Zobrazeno 1 - 10
of 382
pro vyhledávání: '"C. Kent Osborne"'
Autor:
Xiaoyong Fu, Resel Pereira, Chia-Chia Liu, Carmine De Angelis, Martin J. Shea, Sarmistha Nanda, Lanfang Qin, Tamika Mitchell, Maria L. Cataldo, Jamunarani Veeraraghavan, Vidyalakshmi Sethunath, Mario Giuliano, Carolina Gutierrez, Balázs Győrffy, Meghana V. Trivedi, Ofir Cohen, Nikhil Wagle, Agostina Nardone, Rinath Jeselsohn, Mothaffar F. Rimawi, C. Kent Osborne, Rachel Schiff
Publikováno v:
Cell Reports, Vol 42, Iss 8, Pp 112821- (2023)
Summary: Aberrant activation of the forkhead protein FOXA1 is observed in advanced hormone-related cancers. However, the key mediators of high FOXA1 signaling remain elusive. We demonstrate that ectopic high FOXA1 (H-FOXA1) expression promotes estrog
Externí odkaz:
https://doaj.org/article/9ae29d74241a427e80d1e8022dc30c52
Autor:
Varduhi Petrosyan, Lacey E. Dobrolecki, Lillian Thistlethwaite, Alaina N. Lewis, Christina Sallas, Ramakrishnan R. Srinivasan, Jonathan T. Lei, Vladimir Kovacevic, Predrag Obradovic, Matthew J. Ellis, C. Kent Osborne, Mothaffar F. Rimawi, Anne Pavlick, Maryam Nemati Shafaee, Heidi Dowst, Antrix Jain, Alexander B. Saltzman, Anna Malovannaya, Elisabetta Marangoni, Alana L. Welm, Bryan E. Welm, Shunqiang Li, Gerburg M. Wulf, Olmo Sonzogni, Chen Huang, Suhas Vasaikar, Susan G. Hilsenbeck, Bing Zhang, Aleksandar Milosavljevic, Michael T. Lewis
Publikováno v:
iScience, Vol 26, Iss 1, Pp 105799- (2023)
Summary: Although systemic chemotherapy remains the standard of care for TNBC, even combination chemotherapy is often ineffective. The identification of biomarkers for differential chemotherapy response would allow for the selection of responsive pat
Externí odkaz:
https://doaj.org/article/2b0f86504c374089a6c4e5c09a09e1cb
Autor:
Jamunarani Veeraraghavan, Carolina Gutierrez, Vidyalakshmi Sethunath, Sepideh Mehravaran, Mario Giuliano, Martin J. Shea, Tamika Mitchell, Tao Wang, Sarmistha Nanda, Resel Pereira, Robert Davis, Kristina Goutsouliak, Lanfang Qin, Carmine De Angelis, Irmina Diala, Alshad S. Lalani, Chandandeep Nagi, Susan G. Hilsenbeck, Mothaffar F. Rimawi, C. Kent Osborne, Rachel Schiff
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-11 (2021)
Abstract Lapatinib (L) plus trastuzumab (T), with endocrine therapy for estrogen receptor (ER)+ tumors, but without chemotherapy, yielded meaningful response in HER2+ breast cancer (BC) neoadjuvant trials. The irreversible/pan-HER inhibitor neratinib
Externí odkaz:
https://doaj.org/article/9c0763f670574156a633837d6c948965
Autor:
Arturo B. Ramirez, Raksha Bhat, Debashish Sahay, Carmine De Angelis, Hariprasad Thangavel, Sina Hedayatpour, Lacey E. Dobrolecki, Agostina Nardone, Mario Giuliano, Chandandeep Nagi, Mothaffar Rimawi, C. Kent Osborne, Michael T. Lewis, Jackie L. Stilwell, Eric P. Kaldjian, Rachel Schiff, Meghana V. Trivedi
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-10 (2019)
Abstract Background Breast cancer patient-derived xenograft (BC-PDX) models represent a continuous and reproducible source of circulating tumor cells (CTCs) for studying their role in tumor biology and metastasis. We have previously shown the utility
Externí odkaz:
https://doaj.org/article/cda25575e8d7448795627f419d53ae17
Autor:
Hariprasad Thangavel, Carmine De Angelis, Suhas Vasaikar, Raksha Bhat, Mohit Kumar Jolly, Chandandeep Nagi, Chad J. Creighton, Fengju Chen, Lacey E. Dobrolecki, Jason T. George, Tanya Kumar, Noor Mazin Abdulkareem, Sufeng Mao, Agostina Nardone, Mothaffar Rimawi, C. Kent Osborne, Michael T. Lewis, Herbert Levine, Bing Zhang, Rachel Schiff, Mario Giuliano, Meghana V. Trivedi
Publikováno v:
Journal of Clinical Medicine, Vol 8, Iss 11, p 1772 (2019)
Circulating tumor cell clusters (CTCcl) have a higher metastatic potential compared to single CTCs and predict long-term outcomes in breast cancer (BC) patients. Because of the rarity of CTCcls, molecular characterization of primary tumors that give
Externí odkaz:
https://doaj.org/article/d8701f5db2c14c9da8230cc0d4baf25d
Autor:
Kristen L. Karlin, Gourish Mondal, Jessica K. Hartman, Siddhartha Tyagi, Sarah J. Kurley, Chris S. Bland, Tiffany Y.T. Hsu, Alexander Renwick, Justin E. Fang, Ilenia Migliaccio, Celetta Callaway, Amritha Nair, Rocio Dominguez-Vidana, Don X. Nguyen, C. Kent Osborne, Rachel Schiff, Li-Yuan Yu-Lee, Sung Y. Jung, Dean P. Edwards, Susan G. Hilsenbeck, Jeffrey M. Rosen, Xiang H.-F. Zhang, Chad A. Shaw, Fergus J. Couch, Thomas F. Westbrook
Publikováno v:
Cell Reports, Vol 9, Iss 4, Pp 1318-1332 (2014)
Defining the molecular networks that drive breast cancer has led to therapeutic interventions and improved patient survival. However, the aggressive triple-negative breast cancer subtype (TNBC) remains recalcitrant to targeted therapies because its m
Externí odkaz:
https://doaj.org/article/f1e3e5e6d0304dd2bb7aabf105868310
Stay on top of the latest knowledge in the field with this must-have resource for all clinicians who treat breast diseases. Expand your knowledge of every aspect of breast diseases as a diverse and distinguished group of internationally-recognized ex
Publikováno v:
Journal of Clinical Oncology. 41:1331-1338
PURPOSE Immunohistochemistry (IHC) is a newer technique for assessing the estrogen receptor (ER) status of breast cancers, with the potential to overcome many of the shortcomings associated with the traditional ligand-binding assay (LBA). The purpose
Autor:
Jonathan T. Lei, Chen Huang, Ramakrishnan R. Srinivasan, Suhas Vasaikar, Lacey E. Dobrolecki, Alaina N. Lewis, Na Zhao, Jin Cao, Susan G. Hilsenbeck, C. Kent Osborne, Mothaffar Rimawi, Matthew J. Ellis, Varduhi Petrosyan, Alexander B. Saltzman, Anna Malovannaya, John D. Landua, Bo Wen, Antrix Jain, Gerburg M. Wulf, Shunqiang Li, Daniel C. Kraushaar, Tao Wang, Xi Chen, Gloria V. Echeverria, Meenakshi Anurag, Bing Zhang, Michael T. Lewis
Publikováno v:
Cancer Research. 83:P2-23
Background: Triple-negative breast cancer (TNBC) patients frequently receive combination chemotherapy treatment, but a direct comparison of response to carboplatin, docetaxel, and their combination in 50 TNBC patient-derived xenografts (PDXs) showed
Autor:
Snehal Patel, Jaye Thompson, Mira Patel, F. Joseph Daugherty, C. Kent Osborne, Mothaffar Rimawi
Publikováno v:
Cancer Research. 83:OT2-10
Background: GP2 is a biologic nine amino acid peptide of the HER2/neu protein delivered in combination with Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) that stimulates an immune response targeting HER2/neu expressing cancers, the combin